Ifosfamide nephrotoxicity in children: A mechanistic base for pharmacological prevention

Expert Opinion on Drug Safety

Volumn 8, Issue 2, 2009, Pages 155-168

  Hanly, Lauren ^a   Chen, Nancy ^a   Rieder, Michael ^a,d,e   Koren, Gideon ^a,b,c,e,f  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Division of Clinical Pharmacology and Toxicology ^*  (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e CHILDREN S HOSPITAL OF WESTERN ONTARIO   (Canada)

^f WESTERN UNIVERSITY   (Canada)

Author keywords

Antioxidants; Children; Chloroacetaldehyde; Ifosfamide; N acetylcysteine; Nephrotoxicity; Oxidative stress; Prevention

Indexed keywords

ACETYLCYSTEINE; ACROLEIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; CHLOROACETALDEHYDE; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FREE RADICAL; GLUTATHIONE; GLYCINE; HISTIDINE; IFOSFAMIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELATONIN; MESNA; PARACETAMOL; REACTIVE OXYGEN METABOLITE; RESVERATROL; TAURINE; THYMOQUINONE; TUMOR NECROSIS FACTOR ALPHA; ACETALDEHYDE; ALKYLATING AGENT; DRUG DERIVATIVE;

AMINOACIDURIA; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; BICARBONATURIA; CELL PROTECTION; CHILD; CHILD HEALTH; CHILDHOOD CANCER; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CREATININE BLOOD LEVEL; DIABETES INSIPIDUS; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG STRUCTURE; DRUG TRANSFORMATION; FANCONI RENOTUBULAR SYNDROME; GLOMERULAR DYSFUNCTION; GLOMERULUS FILTRATION RATE; GLUCOSURIA; GROUPS BY AGE; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIC RICKETS; KALURIA; KIDNEY CELL; KIDNEY INJURY; KIDNEY METABOLISM; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ACIDOSIS; LIPID PEROXIDATION; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PHOSPHATURIA; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SOLID TUMOR; UREA BLOOD LEVEL; AGE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; KIDNEY DISEASE;

ACETALDEHYDE; ACETYLCYSTEINE; AGE FACTORS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; CHILD; HUMANS; IFOSFAMIDE; KIDNEY DISEASES; OXIDATIVE STRESS; RISK FACTORS;

EID: 66949133232     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330902808169     Document Type: Review

References (112)

1. Dechant KL, Brodgden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991;42:428-467
2. Loos MWJ, Seynaeve C, Werwiej J, Sleijfer S. The Pharmacologic basis of ifosfamide use in adult patients with advances soft tissue sarcomas. Oncologist 2007;12:1351-1360 (Pubitemid 350232609)
3. de Kraker J. Ifosfamide in pediatric oncology. Anti cancer Drugs 1991;2:339-341
4. Pinkerton CR, Pritchard J. A phase II study of ifosfamide in pediatric solid tumours. Cancer Chemother Pharmacol 1989;24(Suppl):S13-5 (Pubitemid 19197355)
5. Pratt CM, Douglass EC, Etcubanas EL, et al. Ifosfamide in pediatric malignant solid tumors. Cancer Chemther Pharmacol 1989;34(Suppl):S24-7 (Pubitemid 19197358)
6. Jurgens H, Treuner H, Winkler K, Gobel U. Ifosfamide in pediatric malignancies. Semin Oncol 1989;16:46-50 (Pubitemid 19116956)
7. Ifosfamide. Pharmacology and clinical results in the treatment of cancer, Preceedings of a symposium. Semin Oncol 1982;9(Suppl 1):1
8. Schein P. Introduction, Preceedings of a symposium. Semin Oncol 1982;9(Suppl 1):75
9. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase ll trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1987;23:311-321 (Pubitemid 17033680)
10. Rodriquez V, McCredie KB, Keating MJ, et al. Iphosfamide therapy for hematological malignancies in patients refractory to prior treatment. Cancer Treat Rep 2003;65(Suppl 2):85-93
11. Johnstone EC, Lind MJ, Griffin MJ, Boddy AV. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemopther Pharmacol 2000;46:433-441
12. Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998;50:107-141 (Pubitemid 28158844)
13. Townsend DM, Deng M, Zhang L, et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1-10 (Pubitemid 36026291)
14. Woodland C, Ito S, Granvil CP, et al. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000;68:109-117
15. Connors TA, Coz PJ, Farmer PB, et al. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem Pharmacol 1974;23:115-129
16. Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 1976;60:437-443
17. Loebstein R, Koren G. Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 1998;101:E8-12
18. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol 2003;41:190-197 (Pubitemid 36910127)
19. Skinner R, Pearson ADJ, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996;348:578-580 (Pubitemid 26283889)
20. Suarez A, McDowell H, Niaudet P, et al. Long-term follow up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International society of pediatric oncology report. J Clin Oncol 1991;9:2177-2182
21. Shore R, Greenberg M, Geary D, Koren G. Ifosfamide-induced nephrotoxicity in children. Pediatr Nephrol 1992;6:162-165
22. Skinner R, Pearson ADJ, Price L. The influence of age on nephrotoxicity following chemotherapy in children. Br J Cancer 1992;66(Suppl 18):30-35
23. Rossi R, Gödde A, Kleinebrand A, et al. Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 1994;12:159-165 (Pubitemid 24020636)
24. Rossi R, Danzebrink S, Hillebrand D, et al. Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum. Med Pediatr Oncol 1994;22:27-32 (Pubitemid 23361825)
25. Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicityand tubular nephrotoxicity by prior cis-diamminedichloroplatinum therapy. Cancer Res 1987;47(5):1457-1460 (Pubitemid 17023223)
26. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in microsomes. Cancer Res 1993;53:5629-5637 (Pubitemid 23360263)
27. Walker D, Flinois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-decholorethylation of ifosfamide. Biochem Pharmacol 1994;47:1157-1163 (Pubitemid 24127929)
28. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000;59;961-972 (Pubitemid 30110812)
29. Springate JE, Van Liew JB. Nephrotoxicity of ifosfamide in rats [letter]. J Appl Toxicol 1995;15:399-402
30. Springate JE, Chan K, Lu H, et al. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell Dev Biol Anim 1999;35:314-317 (Pubitemid 29288354)
31. Dubourg L, Michoudet C, Cochat P, Baverel G. Human kidney tubules detoxify chloroactetaldehyde, a presumed nephrotoxic metabolite of ifsofamide. J Am Soc Nephrol 2001;12:1615-1623 (Pubitemid 32674423)
32. Sarosy G. Semin Oncol 1989;16:2-8
33. Boddy AV, Pearson ADJ, Idle JR, Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in pediatrics. Eur J Cancer 1996;32A:1179-1184 (Pubitemid 26231800)
34. Springate J, Taub M. Ifosfamide toxicity in cultured proximal renal tubule cells. Pediatr Nephrol 2007;22:358-365 (Pubitemid 46766759)
35. Hosseinpour F, Norlin M, Wikvall K. Kidney microsomal 25- and 1-alpha hydroxylase in vitamin D metabolism: catalytic properties, molecular cloning, cellular localization and expression during development. Biochim Phys Acta 2002;1580:133-144 (Pubitemid 34203868)
36. Aleksa K, Ito S, Koren G. Developmental renal tubular toxicity: a hypothetical frame work and experimental approaches. Curr Ther Res Clin Exp 2001;62:930-941 (Pubitemid 34112234)
37. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988;37:301-355 (Pubitemid 18153921)
38. Aleksa K, Ito S, Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 2004;143:159-162 (Pubitemid 38352536)
39. Brock N, Pohl J, Stekar J. Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-I: experimental studies on the urotoxicity of alkylating compounds. Eur J Cancer 1981;16:595-607 (Pubitemid 11047936)
40. Skinner R, Sharkey IM, Pearson ADJ, Craft AW. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 1993;11:173-190 (Pubitemid 23059992)
41. Rossi R. Nephrotoxicity of ifosfamide- moving toward understanding the molecular mechanisms. Nephrol Dial Transplant 1997;12:1091-1092 (Pubitemid 27230536)
42. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol 1996;27:149-155 (Pubitemid 26282094)
43. Rossi R, Godde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17:551-557
44. De Schepper J, Hachimi-Idrissi S, Verboven M, et al. Renal function abnormalities after ifosfamide treatment in children. Acta Pediatrica 1993;82(4):373-376 (Pubitemid 23142853)
45. Al Sheyyab M, Worthington D, Beetham R, Stevens M. The assessment of subclinical ifosfamide-induced renal tubular toxicity using urinary excretion of retinol binding protein. Pediatr Hematol Oncol 1993;10:119-128 (Pubitemid 23151986)
46. Heney D, Wheeldon J, Rushworth P, et al. Progressive renal toxicity due to ifosfamide. Arch Dis Child 1991;66:966-970
47. Rossi R, Kist C, Wurster U, et al. Estimation of ifosfamide/cisplatinum- induced renal toxicity by urinary protein analysis. Pediatr Nephrol 1994;8:151-156 (Pubitemid 24092248)
48. Skinner R, Pearson ADJ, Price L, et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990;65:732-738 (Pubitemid 20220431)
49. Ashraf MS, Brady J, Breatnach F, et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Eur J Pediatr 1994;153:90-94 (Pubitemid 24052700)
50. Smeitink J, Verreussel M, Schroder C, Lippens R. Nephrotoxicity associated with ifosfamide. Eur J Pediatr 1988;148:164-166 (Pubitemid 18276114)
51. DeFronzo RA, Abeloff M, Baurine H, et al. Renal dysfunction after treatment with isophosphamide (NSC-109724). Cancer Chemother Rep 1974;58:375-382
52. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and decarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-1216 (Pubitemid 19220122)
53. Patterson WP, Khojasteh A. Ifosfamide-induced renal tubular defects. Cancer 1989;63:649-651 (Pubitemid 19050264)
54. Sangster G, Kaye SB, Calman KC, Dalton JF. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Canncer Clin Oncol 1984;20:435-436 (Pubitemid 14157824)
55. Heney D, Lewis IJ, Bailey CC. Acute ifosfamide-induced tubular toxicity. Lancet 1989;2:103-104 (Pubitemid 19173319)
56. Devalck C, Ismaili K, Ferster A, Sariban E. Acute ifosfamide-induced proximal tubular toxic reaction [letter]. J Pediatr 1991;118:325-326
57. Pratt CB, Meyer WH, Jenkins JJ, et al. Ifosfamide, Fanconi's syndrome and rickets. J Clin Oncol 1991;9:1495-1499
58. Newbury-Ecob RA, Noble VW, Barbor PRH. Ifosfamide-induced Fanconi's syndrome [letter]. Lancet 1989;1:1328
59. De Schepper J, Stevens G, Verboven M, et al. Ifosfamide-induced Fanconi's syndrome with growth failure in a 2-year old child. Am J Pediatr 1991;13:39-41
60. Stöhr W, Patzer L, Paulides M, et al. Growth impairment after ifosfamide-induced nephrotoxicity in children. Pediatr Blood Cancer 2007;48:571-576 (Pubitemid 46496355)
61. Skinner R, Pearson ADJ, Price L, et al. Hypophosphatemic rickets after ifosfamide treatment in. children BMJ 1989;298:1560-1561
62. Caron HN, Abeling N, van Gennip, et al. Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Med Pediatr Oncol 1992;20:42-47
63. Rossi R, Pleyer J, Schäfers P, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999;32:177-182 (Pubitemid 29095976)
64. Montcrieff M, Foot A. Fanconi syndrome after ifosfamide. Cancer Chemother Pharmacol 1989;23:121-122 (Pubitemid 19022334)
65. Van Gool S, Brock P, Wijndaele G, et al. Reversible hypophosphatemic rickets following ifosfamide treatment. Med Pediatr Oncol 1992;20:254-257
66. Ashraf MS, Skinner R, English MW, et al. Late reversibility of chronic ifosfamide-associated nephrotoxicity in a child. Med Pediatr Oncol 1997;28:62-64 (Pubitemid 27023779)
67. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-1582 (Pubitemid 44547808)
68. Dubourg L, Tanière P, Cochat P, et al. Toxicity of chloroacetaldehyde is similar in adult and pediatric kidney tubules. Pediatr Nephrol 2002;17:97-103 (Pubitemid 36067978)
69. Brüggemann SK, Radike K, Braasch K, et al. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. Cancer Chemother Pharmacol 2006;57:349-356
70. Takahashi K, Sakurai K, Takahashi K, et al. Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. Anticancer Drugs 2007;18:543-553 (Pubitemid 46597409)
71. Kim JS, He L, Lemasters JJ. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biophys Biochem Res Commun 2003;304:463-470 (Pubitemid 36506518)
72. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989;6:593-597 (Pubitemid 19147809)
73. Sener G, Sehirli O, Yegen BC, et al. Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. J Pineal Res 2004;37:17-25 (Pubitemid 38976501)
74. Eiam-ong S, Spohn M, Kurtzman NA, Sabatini S. Insights into the biochemical mechanism of maleic acid-induced Fanconi syndrome. Kidney Int 1995;48:1542-1548
75. Benesic A, Schwerdt G, Mildenberger S, et al. Disturbed Ca2+-signaling by chloroacetaldehyde: a possible cause for chronic ifosfamide nephrotoxicity. Kidney Int 2005;68:2029-2041 (Pubitemid 43117778)
76. Sehirli O, Sakarcan A, Velio lu-O ünç A, et al. Resveratrol improves ifosfamide-induced Fanconi syndrome in rats. Toxicol Appl Pharmacol 2007;222:33-41
77. Lash LH. Toxicology of the kidney. Third edition. In: Tarloff JB, Lash LH, editors, Role of cellular energetics in nephrotoxicity. Chapter 11. CRC press, Denver, MA. 2005. p. 433
78. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997;185:1481-1486 (Pubitemid 27187604)
79. Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 1997;57:1835-1840 (Pubitemid 27209706)
80. Schwerdt G, Gordjani N, Benesic A, et al. Chloroacetaldehyde- and acrolein-induced death of human proximal tubule cells. Pediatr Nephrol 2006;21:60-67 (Pubitemid 43040196)
81. Sen CK. Redox signaling and the emerging therapeutic potential of thiol antioxidants. Biochem Pharmacol 1998;55:1747-1758 (Pubitemid 28305256)
82. Berry CA, Rector FC Jr. Renal transport of glucose, amino acid, sodium, chloride, and water. Fourth edition. In: Brenner BM, Rector FC Jr, editors, The kidney. Chapter 7. WB Saunders Co, Philadelphia, PA, 1991. p. 245-257
83. Harman AW, Maxwell MJ. An evaluation of the role of calcium in cell injury. Annu Rev Pharmacol Toxicol 1995;35:129-144
84. Ishii Y, Partridge CA, Del Vecchio PJ, Malik AB. Tumor necrosis factor-alpha-mediated decrease in glutathione increases the sensitivity of pulmonary vascular endothelial cells to H2O2. J Clin Invest 1992;89:794-802
85. Chen N, Aleksa K, Woodland C, et al. N-acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. Br J Pharmacol 2008;153:1364-1372
86. Corda S, Laplace C, Vicaut E, Duranteau J. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-α is mediated by ceramide. Am J Respir Cell Mol Biol 2001;24:762-768 (Pubitemid 32550600)
87. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNF alpha in pulmonary pathophysiology. Respir Res 2006;7:125 (Pubitemid 44637860)
88. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharm 1999;39:454-461 (Pubitemid 29356465)
89. Skinner R, Cotterill SJ, Stevens MCG. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG late effects group study. Brit J Cancer 2000;82:1638-1645 (Pubitemid 30229572)
90. Aleksa K, Woodland C, Koren G. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatr Nephrol 2001;16:1153-1158 (Pubitemid 34026742)
91. Aleksa K, Halachmi N, Ito S, Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 2004;144:285-293 (Pubitemid 40018015)
92. Soucek P, Zuber R, Anzenbacherova E, et al. Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. BMC Pharmacol 2001;1:11-15 (Pubitemid 38740045)
93. Zuber R, Anzenbacherova E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002;6:189-198 (Pubitemid 44137197)
94. Niederle N, Schuelen ME, Cremer M, et al. Ifosfamide in combination chemotherapy for sarcomas and testicular carcinomas. Cancer Treat Rev 1983;10(Suppl A):129-135 (Pubitemid 14249409)
95. Womer RB, Pritchard J, Barrat TM. Renal toxicity of cisplatin in children. J Pediatr 1985;106:659-663 (Pubitemid 15080566)
96. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity: a review. Cancer Chemother Pharmacol 1989;25:1-9 (Pubitemid 20000790)
97. Zaki EL, Springate JE, Taub M. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubular cells. Toxicol In Vitro 2003;17:397-402 (Pubitemid 36776782)
98. Chen N, Aleksa K, Woodland C, et al. The effect of N-acetylcysteine on ifosfamide-induced nephrotoxicity; in vitro studies in renal tubular cells. Transl Res 2007;150:51-57 (Pubitemid 46935594)
99. Tylicki L, Ruthowski B, Horl WH. Antioxidants: a possible role in kidney protection. Kidney Blood Press Res 2003;26:303-314 (Pubitemid 37465038)
100. Badary O. Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 1999;67:135-142 (Pubitemid 29421667)
101. Badary O. Taurine attenuates Fanconi syndrome induced by ifosfamide without compromising its antitumor activity. Oncol Res1998;10:355-360
102. Bardary O. L-Histidinol attenuates Fanconi syndrome induced by ifosfamide in rats. Exp Nephrol 1999;7:323-327 (Pubitemid 29361672)
103. Nissim I, Weinberg JM. Glycine attenuates Fanconi syndrome induced by maleate or ifosfamide in rats. Kidney Int 1996;49:684-689 (Pubitemid 26093077)
104. Weinberg JM, Davis JA, Abarzua M, Rajan T. Cytoprotection effects of glycine and glutathione against hypoxic injury to renal tubules. J Clin Invest 1987;80:1446-1454 (Pubitemid 18027789)
105. Weinberg JM, Venkatachalam MA, Garza-Quintero R, et al. Structural requirements for protection by small amino acids against hypoxic injury in kidney proximal tubules. FASEB J 1990;4:3347-3354 (Pubitemid 120012583)
106. Baines AD, Shaikh N, Ho P. Mechanisms of perfused kidney cytoprotection by alanine and glycine. Am J Physiol 1990;259:F80-7 (Pubitemid 20246420)
107. Marzullo L. An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr 2005;17:239-245 (Pubitemid 40516108)
108. Kelly GS. Clinical applications of N-acetylcysteine. Altern Med Rev 1998;3:114-127 (Pubitemid 128709607)
109. De Vries N, De Flora S. N-acetyl-l-cysteine. J Cell Biochem 1993;17(Suppl):270-277
110. Borgstrom L, Kagedal B, Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 1986;31:217-222 (Pubitemid 17014593)
111. Chen N, Aleksa K, Woodland C, et al. Prevention of ifosfamide nephrotoxicity by N-acetylcysteine: clinical pharmacokinetic considerations. Can J Clin Pharmacol 2007;14:246-250 (Pubitemid 47324698)
112. Hall JE. The promise of translational physiology. Am J Physiol Lung Cell Mol Physiol 2002;283:L235-236 (Pubitemid 34803977)